Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives Consensus Recommendation of “Hold” from Brokerages

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has been assigned an average recommendation of “Hold” from the twenty-three analysts that are presently covering the company, Marketbeat.com reports. Three analysts have rated the stock with a sell recommendation, twelve have issued a hold recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokers that have covered the stock in the last year is $102.3333.

ZBH has been the topic of several research analyst reports. Wells Fargo & Company reduced their price objective on Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 29th. BMO Capital Markets set a $95.00 target price on shares of Zimmer Biomet in a research note on Wednesday. Leerink Partners assumed coverage on shares of Zimmer Biomet in a report on Monday, April 13th. They set a “hold” rating and a $101.00 target price on the stock. Robert W. Baird set a $92.00 price target on shares of Zimmer Biomet in a report on Wednesday, April 29th. Finally, Wall Street Zen downgraded shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th.

Zimmer Biomet Trading Down 2.0%

Shares of NYSE ZBH opened at $87.65 on Thursday. The stock’s 50 day moving average price is $85.90 and its two-hundred day moving average price is $89.75. Zimmer Biomet has a 52-week low of $79.12 and a 52-week high of $108.29. The stock has a market capitalization of $16.96 billion, a P/E ratio of 22.77, a PEG ratio of 2.63 and a beta of 0.46. The company has a quick ratio of 0.95, a current ratio of 1.73 and a debt-to-equity ratio of 0.50.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, topping analysts’ consensus estimates of $1.86 by $0.23. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The company had revenue of $2.09 billion for the quarter, compared to the consensus estimate of $2.07 billion. During the same quarter last year, the business posted $1.81 EPS. Zimmer Biomet’s quarterly revenue was up 9.3% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, analysts anticipate that Zimmer Biomet will post 8.48 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Thursday, June 25th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Thursday, June 25th. Zimmer Biomet’s payout ratio is presently 24.94%.

Insider Activity at Zimmer Biomet

In other news, insider Sang Yi sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the transaction, the insider directly owned 27,251 shares of the company’s stock, valued at approximately $2,252,022.64. This represents a 15.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.28% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. M&T Bank Corp increased its position in Zimmer Biomet by 15,705.6% in the fourth quarter. M&T Bank Corp now owns 3,571,595 shares of the medical equipment provider’s stock worth $321,158,000 after buying an additional 3,548,998 shares during the period. Norges Bank acquired a new position in shares of Zimmer Biomet during the fourth quarter valued at $221,234,000. Franklin Resources Inc. grew its position in shares of Zimmer Biomet by 43.2% during the fourth quarter. Franklin Resources Inc. now owns 6,685,987 shares of the medical equipment provider’s stock worth $601,204,000 after acquiring an additional 2,017,857 shares during the last quarter. Auto Owners Insurance Co grew its position in shares of Zimmer Biomet by 8,892.0% during the fourth quarter. Auto Owners Insurance Co now owns 2,009,712 shares of the medical equipment provider’s stock worth $180,713,000 after acquiring an additional 1,987,362 shares during the last quarter. Finally, Dodge & Cox increased its holdings in shares of Zimmer Biomet by 5.1% in the 3rd quarter. Dodge & Cox now owns 23,216,173 shares of the medical equipment provider’s stock worth $2,286,793,000 after acquiring an additional 1,118,710 shares during the period. 88.89% of the stock is currently owned by institutional investors.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.